MOLECULAR PARTNERS AG (MOLN): Price and Financial Metrics
GET POWR RATINGS... FREE!
MOLN Stock Price Chart Interactive Chart >
MOLN Price/Volume Stats
| Current price | $7.22 | 52-week high | $32.04 |
| Prev. close | $7.08 | 52-week low | $5.92 |
| Day low | $7.02 | Volume | 61,200 |
| Day high | $7.32 | Avg. volume | 41,046 |
| 50-day MA | $15.57 | Dividend yield | N/A |
| 200-day MA | $19.01 | Market Cap | 234.66M |
MOLECULAR PARTNERS AG (MOLN) Company Bio
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials.
Latest MOLN News From Around the Web
Below are the latest news stories about Molecular Partners Ag that investors may wish to consider to help them evaluate MOLN as an investment opportunity.
Molecular Partners to Present at Upcoming Healthcare Investor ConferenceZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET. The webcasted prese |
Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients. Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Enc |
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for ensovibep, a DARPin antiviral therapeutic candidate |
3 Stocks That Have Soared as the Market Sank: Are They Buys Now?It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients. |
Novartis Hopes to Have Another COVID Therapy on the WayNovartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep. |
MOLN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -39.12% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -62.36% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...